{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:17:13Z","timestamp":1773987433406,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Domestic Animal Endocrinology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.domaniend.2019.07.004","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T10:03:24Z","timestamp":1565863404000},"page":"106376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-2812","authenticated-orcid":false,"given":"A.","family":"Gal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Weidgraaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2323-3336","authenticated-orcid":false,"given":"P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lopez-Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Malabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-9308","authenticated-orcid":false,"given":"R.","family":"Burchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.domaniend.2019.07.004_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (sglt) inhibitors. Systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (depict-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.domaniend.2019.07.004_bib3","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the depict-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.domaniend.2019.07.004_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/sj.ki.5002383","article-title":"Regulatory mechanisms of na(+)\/glucose cotransporters in renal proximal tubule cells","author":"Lee","year":"2007","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.domaniend.2019.07.004_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s12325-016-0379-5","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review","volume":"33","author":"Kalra","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.domaniend.2019.07.004_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes","volume":"64","author":"De Nicola","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.domaniend.2019.07.004_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.domaniend.2019.07.004_bib8","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.domaniend.2019.07.004_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ASN.0000051700.07403.27","article-title":"Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view","volume":"14","author":"Vallon","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.domaniend.2019.07.004_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"Pksolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.domaniend.2019.07.004_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/chromsci\/bmv040","article-title":"High-performance liquid-chromatographic analysis of plasma iohexol concentrations","volume":"53","author":"Schwertner","year":"2015","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.domaniend.2019.07.004_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/157339908786241151","article-title":"Insights into the regulation of renal hemodynamic function in diabetic mellitus","volume":"4","author":"Cherney","year":"2008","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.domaniend.2019.07.004_bib14","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/ndt\/gfq008","article-title":"Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the african region","volume":"25","author":"Pruijm","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.domaniend.2019.07.004_bib15","first-page":"F65","article-title":"Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback","volume":"252","author":"Woods","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.domaniend.2019.07.004_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00279944","article-title":"Renal enlargement: comparative autoradiographic studies of 3h-thymidine uptake in diabetic and uninephrectomized rats","volume":"25","author":"Rasch","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.domaniend.2019.07.004_bib17","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.domaniend.2019.07.004_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (sglt2) inhibitors: a review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.domaniend.2019.07.004_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cvsm.2012.11.002","article-title":"Diabetes and the kidney in human and veterinary medicine","volume":"43","author":"Bloom","year":"2013","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"10.1016\/j.domaniend.2019.07.004_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0300985813516645","article-title":"Renal morphology in cats with diabetes mellitus","volume":"51","author":"Zini","year":"2014","journal-title":"Vet Pathol"},{"key":"10.1016\/j.domaniend.2019.07.004_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.tcam.2011.04.005","article-title":"The prevalence of microalbuminuria and proteinuria in cats with diabetes mellitus","volume":"26","author":"Al-Ghazlat","year":"2011","journal-title":"Top Companion Anim Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jvim.14902","article-title":"Symmetric dimethylarginine in cats with hypertrophic cardiomyopathy and diabetes mellitus","volume":"32","author":"Langhorn","year":"2018","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib23","first-page":"647","article-title":"Microalbuminuria in dogs with diabetes mellitus","volume":"21","author":"Cavalcante","year":"2007","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jvim.12286","article-title":"Longitudinal prevalence of hypertension, proteinuria, and retinopathy in dogs with spontaneous diabetes mellitus","volume":"28","author":"Herring","year":"2014","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2019.07.004_bib25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2460\/javma.1998.213.06.822","article-title":"Systemic hypertension and proteinuria in dogs with diabetes mellitus","volume":"213","author":"Struble","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.domaniend.2019.07.004_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.15277\/bjdvd.2014.047","article-title":"Dapagliflozin: clinical practice compared with pre-registration trial data","volume":"14","author":"McGovern","year":"2014","journal-title":"Br J Diabetes Vasc Dis"}],"container-title":["Domestic Animal Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724019300475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724019300475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:51:58Z","timestamp":1760035918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0739724019300475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"alternative-id":["S0739724019300475"],"URL":"https:\/\/doi.org\/10.1016\/j.domaniend.2019.07.004","relation":{},"ISSN":["0739-7240"],"issn-type":[{"value":"0739-7240","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats","name":"articletitle","label":"Article Title"},{"value":"Domestic Animal Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.domaniend.2019.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106376"}}